Association Between Clozapine Exposure and Risk of Hematologic Malignancies in Veterans With Schizophrenia

J Clin Psychiatry. 2024;85(2):23m15149

Abstract

Objective: The objective of this study was to examine the relationship between clozapine use and hematologic malignancies, using national administrative data from the United States Veterans Health Administration (VHA).

Methods: This case-control study of veterans with schizophrenia matched cases with incident hematologic malignancy to 10 controls without hematologic malignancy by gender, age, and time since first schizophrenia diagnosis from October 1999, the beginning of VHA data archives, to June 2022. Schizophrenia diagnoses were identified using International Classification of Diseases, Ninth Revision, code 295.x and International Statistical Classification of Diseases, Tenth Revision, codes F20.x and F25.x from inpatient hospitalization and outpatient encounter data. Additional inclusion criteria were age 18–85 years, no prior history of malignancy, and at least 1 year of antipsychotic exposure. Clozapine exposure was assessed using 3 metrics: any exposure, years of exposure, and cumulative defined daily doses (DDD). Conditional multivariable logistic regression was used to adjust for nonmatched confounding variables.

Results: A total of 2,306 veterans with schizophrenia were identified with an incident diagnosis of hematologic malignancy and matched to 23,043 controls. Any prior clozapine exposure was more commonly observed among cases (5.3%) than controls (4.1%) and was significantly different after adjustment (odds ratio [OR], 1.31; 95% CI, 1.08–1.60). Risk was dose-dependent, where cumulative clozapine exposures from 3,000 to 4,999 DDD (OR, 1.78; 95% CI, 1.13–2.79) and ≥5,000 DDD (OR, 1.81; 95% CI, 1.24–2.64) were significantly associated with malignancy risk. Similarly, clozapine exposure of 5 or more years was associated with malignancy risk (OR, 1.88; 95% CI, 1.43–2.47).

Conclusion: Consistent with prior report, this study observed an increased risk of hematologic malignancy associated with clozapine exposure. These findings suggest patients receiving clozapine use, particularly those with long-term use, should be closely monitored for hematologic malignancy.

J Clin Psychiatry 2024;85(2):23m15149

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (18)

Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18(1):39–60. PubMed CrossRef
Wagner E, Siafis S, Fernando P, et al. Efficacy and safety of clozapine in psychotic disorders – a systematic quantitative meta-review. Transl Psychiatry. 2021;11(1):487. PubMed
Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. PubMed CrossRef
Iqbal E, Govind R, Romero A, et al. The side effect profile of clozapine in real world data of three large mental health hospitals. PLoS One. 2020;15(12):e0243437. PubMed CrossRef
Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020;99(11):2477–2482. PubMed CrossRef
Chrétien B, Lelong-Boulouard V, Chantepie S, et al. Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase^®. Psychol Med. 2021;51(9):1459–1466. PubMed
Tiihonen J, Tanskanen A, Bell JS, et al. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. Lancet Psychiatry. 2022;9(5):353–362. PubMed CrossRef
Dawson JL, Sluggett JK, Procter NG, et al. Hematological and other cancers in people using clozapine: analysis of Australian spontaneous reports between 1995 and 2020. J Clin Psychopharmacol. 2023;43(4):333–338. PubMed CrossRef
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. Accessed April 27, 2023. https://www.whocc.no/atcddd/indexdatabase
Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51. PubMed CrossRef
Taipale H, Tanskanen A, Mehtälä J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68. PubMed CrossRef
Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull. 2019;45(2):315–329. PubMed CrossRef
Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. PubMed CrossRef
Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235. PubMed CrossRef
US Department of Veterans Affairs. Veterans’ diseases associated with Agent Orange. Accessed March 19, 2023. https://www.publichealth.va.gov/exposures/agentorange/conditions/index.asp
Nooka AK, Lonial S, Boise LH, et al. Risk factors for development of myeloma: role of smoking and alcohol. Blood. 2014;124(21):2604.
de Leon J, De Las Cuevas C, Sanz EJ, et al. Clozapine and the risk of haematological malignancies. Lancet Psychiatry. 2022;9(7):537–538. PubMed
Schulte PF, Cohen D, Veerman SR, et al. Clozapine and the risk of haematological malignancies. Lancet Psychiatry. 2022;9(7):538–539. PubMed CrossRef